Trials / Unknown
UnknownNCT02211443
Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
A Phase I Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of SCT200, a Recombinant Full Human Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody，in Patients With Metastatic Colorectal Cancer Following Fluoropyrimidine, Irinotecan and Oxaliplatine Chemotherapy Regiment
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether SCT200 is safe and tolerant in the treatment of metastatic colorectal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant full human Anti-EGFR Monoclonal Antibody |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2014-08-07
- Last updated
- 2015-04-09
Source: ClinicalTrials.gov record NCT02211443. Inclusion in this directory is not an endorsement.